Technical Analysis for CBLI - Cleveland BioLabs, Inc.

Grade Last Price % Change Price Change
grade F 1.47 -3.29% -0.05
CBLI closed down 3.29 percent on Friday, May 24, 2019, on 4 percent of normal volume.

Earnings due: May 28

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CBLI trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
MACD Bearish Centerline Cross Bearish -3.29%
Narrow Range Bar Range Contraction -3.29%
NR7 Range Contraction -3.29%
Inside Day Range Contraction -3.29%
20 DMA Resistance Bearish -1.34%
Earnings Movers Other -1.34%
Down 3 Days in a Row Weakness -1.34%

Older signals for CBLI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Cleveland BioLabs, Inc., a clinical-stage biotechnology company, engages in the research, development, and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation, and counteract the genotoxic effects of radio- and chemotherapies for oncology patients. Its lead drug is Entolimod, which is being developed for radiation countermeasure and cancer treatment. The company's products candidates also include CBL0102, which is undergoing a Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and CBL0137, which is in multi-center, single agent, dose escalation Phase I study of the oral formulation in subjects with advanced solid tumors. In addition, it has pre-clinical stage products candidates, such as CBLB612, an inducer and mobilizer of hematopoietic stem cells; Revercom, a cancer drug candidate comprising a liposome-packaged proprietary small molecule named Reversan; Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin; Arkil, a prospective treatment for prostate cancer; Antimycon, a proprietary small molecule lead compound generated to selectively target and inactivate oncoproteins of the Myc family; and Xenomycin family of compounds, which have a range of potential applications as antimicrobial and anti-fungal agents. The company has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Medicine Biotechnology Cancer Clinical Medicine Treatment Of Cancer Solid Tumors Chemotherapy Stem Cells Cancer Treatments Radiation Prostate Cancer Cancer Treatment Advanced Solid Tumors
Is CBLI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.16
52 Week Low 1.0
Average Volume 25,819
200-Day Moving Average 1.6585
50-Day Moving Average 1.5838
20-Day Moving Average 1.5432
10-Day Moving Average 1.5745
Average True Range 0.0964
ADX 32.69
+DI 15.0778
-DI 12.9577
Chandelier Exit (Long, 3 ATRs ) 1.4108
Chandelier Exit (Short, 3 ATRs ) 1.6992
Upper Bollinger Band 1.7088
Lower Bollinger Band 1.3776
Percent B (%b) 0.28
BandWidth 21.461897
MACD Line -0.0096
MACD Signal Line 0.002
MACD Histogram -0.0116
Fundamentals Value
Market Cap 16.58 Million
Num Shares 11.3 Million
EPS -0.67
Price-to-Earnings (P/E) Ratio -2.19
Price-to-Sales 12.32
Price-to-Book 7.79
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.56
Resistance 3 (R3) 1.57 1.55 1.55
Resistance 2 (R2) 1.55 1.53 1.55 1.54
Resistance 1 (R1) 1.51 1.51 1.50 1.50 1.53
Pivot Point 1.49 1.49 1.49 1.49 1.49
Support 1 (S1) 1.45 1.47 1.44 1.44 1.41
Support 2 (S2) 1.43 1.45 1.43 1.40
Support 3 (S3) 1.39 1.43 1.40
Support 4 (S4) 1.38